These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30895387)

  • 1. Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis.
    Gao J; Jones J; Damato EM; Coles A
    J Neurol; 2019 Jun; 266(6):1539-1540. PubMed ID: 30895387
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term remission of tumefactive relapsing multiple sclerosis after alemtuzumab rescue treatment in an adolescent patient.
    Baroncini D; Annovazzi P; Guaschino C; Minonzio G; Hametner S; Stadelmann C; Comi G; Ghezzi A; Zaffaroni M
    Mult Scler Relat Disord; 2020 Jun; 41():102061. PubMed ID: 32203930
    [No Abstract]   [Full Text] [Related]  

  • 3. Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab for Relapsing-Remitting Multiple Sclerosis.
    Penkert H; Delbridge C; Wantia N; Wiestler B; Korn T
    JAMA Neurol; 2016 Jun; 73(6):757-9. PubMed ID: 27043129
    [No Abstract]   [Full Text] [Related]  

  • 4. Dominus effect: challenging complications of alemtuzumab-related thyroid autoimmunity.
    Bianco A; Nicoletti T; Traini E; Del Giacomo P; Del Gatto V; Lucchini M; Rota CA; Mirabella M
    J Endocrinol Invest; 2020 Aug; 43(8):1159-1161. PubMed ID: 32130689
    [No Abstract]   [Full Text] [Related]  

  • 5. Alemtuzumab-induced red cell aplasia and other immune cytopenias: not so 'pure'.
    Aitken L; Patel R; D'Rozario J; Choi P
    Immunotherapy; 2022 Feb; 14(2):95-99. PubMed ID: 34743591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab.
    Gaitán MI; Ysrraelit MC; Correale J
    JAMA Neurol; 2017 Sep; 74(9):1143-1144. PubMed ID: 28715536
    [No Abstract]   [Full Text] [Related]  

  • 7. New Warning for the Multiple Sclerosis Drug Alemtuzumab.
    Aschenbrenner DS
    Am J Nurs; 2019 Mar; 119(3):21. PubMed ID: 30801313
    [No Abstract]   [Full Text] [Related]  

  • 8. Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.
    Barton J; Hardy TA; Riminton S; Reddel SW; Barnett Y; Coles A; Barnett MH
    Neurology; 2017 Mar; 88(10):1004-1006. PubMed ID: 28179462
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune-Mediated Hepatitis Induced by Therapy With Alemtuzumab in a Patient With Multiple Sclerosis.
    Bolte FJ; Schmidt HH; Schlevogt B
    Hepatology; 2021 Jan; 73(1):460-463. PubMed ID: 32583445
    [No Abstract]   [Full Text] [Related]  

  • 10. [Vitiligo with Koebner phenomenon in a patient with multiple sclerosis treated with alemtuzumab].
    Eichau S; Lopez-Ruiz R; Ruiz-Pena JL; Paramo MD; Navarro-Mascarell G; Izquierdo G
    Rev Neurol; 2018 Jun; 66(11):395-396. PubMed ID: 29790573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune storm following alemtuzumab.
    Chan C; Beauchemin P; Sayao AL; Carruthers M
    BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35760506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early neutropenia with thrombocytopenia following alemtuzumab treatment for multiple sclerosis: case report and review of literature.
    Maniscalco GT; Cerillo I; Servillo G; Napolitano M; Guarcello G; Abate V; Improta G; Florio C
    Clin Neurol Neurosurg; 2018 Dec; 175():134-136. PubMed ID: 30419425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease.
    Alcalá C; Pzére-Miralles F; Gascón F; Evole M; Estutia M; Gil-Perotín S; Casanova B
    Mult Scler Relat Disord; 2019 Jan; 27():406-408. PubMed ID: 30530069
    [No Abstract]   [Full Text] [Related]  

  • 14. Glomerulonephritis With Positive Anti-Glomerular Basement Membrane Antibodies Following Alemtuzumab Treatment.
    White E; Watson A; Holian J; McGuigan C; O'Riordan S
    Ir Med J; 2020 Mar; 113(3):41. PubMed ID: 32815683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis.
    Canham LJW; Manara A; Fawcett J; Rolinski M; Mortimer A; Inglis KEA; Cottrell DA
    Mult Scler Relat Disord; 2018 Aug; 24():38-41. PubMed ID: 29885597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe bradycardia: An unreported adverse infusion-associated reaction (IAR) with alemtuzumab.
    Nerrant E; Thouvenot E; Castelnovo G
    Rev Neurol (Paris); 2017 Mar; 173(3):175-176. PubMed ID: 28320519
    [No Abstract]   [Full Text] [Related]  

  • 17. Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis.
    Yann K; Jackson F; Sharaf N; Mihalova T; Talbot P; Rog D; Pace A
    Mult Scler Relat Disord; 2017 May; 14():1-3. PubMed ID: 28619423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review.
    Federle L; Puthenparampil M; Stenta G; Paolo G; Francesco P
    Mult Scler Relat Disord; 2019 May; 30():262-264. PubMed ID: 30851640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACUTE POSTERIOR MULTIFOCAL PLACOID PIGMENT EPITHELIOPATHY AFTER IMMUNIZATION WITH MULTIPLE VACCINES.
    Kraemer LS; Montgomery JR; Baker KM; Colyer MH
    Retin Cases Brief Rep; 2022 Jan; 16(1):16-19. PubMed ID: 31990820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alemtuzumab-associated diffuse alveolar damage - a case report.
    Bayas A; Menacher M; Schwaiblmair M; Märkl B; Naumann M
    BMC Neurol; 2020 Sep; 20(1):357. PubMed ID: 32967641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.